Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
156
resultados
Última actualización
10/10/2025 [06:46:00]
Resultados 75 a 100 de 156
Resumen de: US2025281430A1
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and/or reducing relapse of agitation in Alzheimer's disease.
Resumen de: US2025281488A1
The present invention relates to inhibitors of Valosin-containing protein (VCP or p97) and the use thereof in the treatment or prevention of diseases such as amyotrophic lateral sclerosis (ALS). In particular the present invention provides VCP inhibitors for use in a method of treating or preventing ALS wherein the subject has been identified as not having a disease-causing genetic mutation in a VCP gene (non-VCP-associated ALS). The invention also relates to methods of identifying a patient as not having a disease-causing mutation in a VCP gene.
Resumen de: EP4613277A1
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Resumen de: EP4613281A1
The present invention relates to a composition for preventing, ameliorating, or treating Alzheimer's disease comprising grapevine stem extract or a compound isolated therefrom as an effective component. Specifically, as the grapevine stem extract and vitisin A as an effective component of the present invention exhibit an excellent effect of inhibiting infection with the herpes simplex virus and inhibiting Alzheimer-causing factors in the brain tissue of animal models infected with the herpes simplex virus, the composition of the present invention can be advantageously used as an agent for treating Alzheimer's disease or a functional health food or an animal feed additive for preventing or ameliorating Alzheimer's disease.
Resumen de: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Resumen de: EP4613278A1
The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.
Resumen de: WO2025184490A1
The present disclosure provides methods of treating Alzheimer's Disease (AD) using Compound (I) as represented by the structure below: Formula should be inserted here or a free base or pharmaceutically acceptable salt thereof.
Resumen de: WO2025181155A1
This application relates to polypeptide agents and compositions specifically binding human beta-glucocerebrosidase (GCase, GBA1). Particularly, immunoglobulin single variable domains (ISVDs) are described which allosterically bind human GCase, thereby positively modulating GCase in its stability and/or catalytic activity. The invention relates further to vectors and nucleic acids encoding such ISVD-based modulators. Also encompassed are compositions, in particular pharmaceutical compositions, containing such ISVD modulators. The GCase-specific allosteric modulators, specifically the ISVDs and compositions described herein, may be used for prevention and/or treatment of GCase-related diseases, including Gaucher disease (GD) and Parkinson's disease (PD).
Resumen de: AU2025213702A1
Abstract Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease. Abstract Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.
Resumen de: AU2025217319A1
Described herein are methods for treating a subject having or at risk of developing Parkinson’s disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents. Described herein are methods for treating a subject having or at risk of developing Parkinson's disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents. ug e s c r i b e d h e r e i n a r e m e t h o d s f o r t r e a t i n g a s u b j e c t h a v i n g o r a t r i s k o f d e v e l o p i n g u g a r k i n s o n ' s d i s e a s e , b y a d m i n i s t e r i n g p l u r i p o t e n t c e l l s t h a t e x p r e s s g l u c o c e r e b r o s i d a s e ( ) o r p l u r i p o t e n t c e l l s t h a t e x p r e s s a n d o n e o r m o r e - p r o m o t i n g a g e n t s t o t h e s u b j e c t l s o d i s c l o s e d a r e c o m p o s i t i o n s c o m p r i s i n g p l u r i p o t e n t c e l l s e x p r e s s i n g , s u c h a s p l u r i p o t e n t c e l l s e x p r e s s i n g a n d o n e o r m
Resumen de: AU2023427408A1
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and/or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson Disease or related condition resulting from a deficiency in the quantity and/or function of GBA gene product or associated with decreased expression or protein levels of GCase protein.
Resumen de: US2025277040A1
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Resumen de: US2025277203A1
The invention relates to expression vectors, and pharmaceutical compositions, and kits comprising the vectors, and, in particular, their use in methods for treating Parkinson's disease (PD), DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.
Resumen de: US2025275953A1
The present disclosure relates to a method of treating, or delaying, inhibiting, or suppressing of the progression of, a neurodegenerative disease such as, for example, early-stage Parkinson's disease comprising administering a c-Abl inhibitor (such as vodobatinib, or a pharmaceutically acceptable salt thereof) to a subject in need thereof.
Resumen de: US2025275935A1
Compositions and products (e.g., kits, medical devices, medicaments), which incorporate the compositions, comprising a tetrahydrocannabinol (THC) compound and melatonin compound are provided, Methods for treatment using the compositions and products, methods for diagnosis before or after treatment, and processes for formulating the compositions or manufacturing the products are also provided. They address the need for new treatments of cognitive and perceptual deficits, neuropsychiatric symptoms, neurodegenerative diseases, and neurologic disorders. The inventors discovered therapeutically effective amounts of TI-IC and melatonin can be administered to treat patients, without need for an entourage effect or requirement of cannabidiol (CBD) and other cannabinoid compounds. Optionally, polyphenolic compounds (e.g., curcumin-related compounds, rutin-related compounds) and/or Vitamin E-related compounds (e.g., mixed tocopherols, alpha-tocopherol, beta-tocopherol, gamma-tocopherol) may be administered together with or separately from TI-IC and melatonin compounds.
Resumen de: US2025275936A1
Compositions and methods for treating a cancer or a neurological disease. A method of treating a cancer or a neurological disease comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin C, folic acid, a chemotherapeutic agent, and zafirlukast. A method of treating amyotrophic lateral sclerosis comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin C, folic acid, a chemotherapeutic agent, and zafirlukast.
Resumen de: WO2025184649A1
The present disclosure provides methods related to treating neurodegeneration and neuroinflammation. In particular, the present disclosure identifies YTH domain-containing family protein 1 (YTHDF1) as a novel therapeutic target for Alzheimer's disease. Embodiments of the present disclosure provide methods of therapy for neurodegenerative disease that involve inhibiting YTHDF1 to induce attenuation of chronic neuroinflammation.
Resumen de: WO2025184593A1
The present disclosure provides methods for preventing or treating a neurodegenerative disorder in a subject, where the neurodegenerative disorder is one characterized by a deposition of abnormal tau protein in the brain of the subject. The method generally includes administering to the subject a therapeutically effective amount of a drug that is a tau propagation antagonist.
Resumen de: WO2025184056A1
Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.
Resumen de: WO2025183416A1
The present invention relates to a composition for treating cognitive dysfunction, specifically Alzheimer's disease. The composition according to one aspect can inhibit or reduce the accumulation of amyloid aggregates and phosphorylated tau aggregates, and improve memory and cognitive function.
Resumen de: WO2025181805A1
Provided herein a method for treatment, prevention, alleviation, delaying symptom onset, or slowing of progression of Huntington disease, comprising administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof and at least one composition comprising sigma 2 antagonist agent.
Resumen de: WO2025180180A1
Provided is use of a cell-free fat extract (CEFFE Pro 2.0) in the preparation of a pharmaceutical composition or a health product composition for preventing and/or treating Alzheimer's disease. Treatment of a Caenorhabditis elegans pathology model of Alzheimer's disease with the cell-free fat extract demonstrates that the cell-free fat extract can effectively prolong paralysis of Caenorhabditis elegans of Alzheimer's disease. In a cell experiment, the cell-free fat extract has the effects of promoting the proliferation of SH-SY5Y cells and improving the cell growth state, inhibiting cell agglomeration and shrinkage, and inhibiting cellular damage. The provided cell-free fat extract exhibits potential against Alzheimer's disease and can be used for preparing a pharmaceutical composition or a health product composition for preventing and/or treating Alzheimer's disease.
Resumen de: US2025275934A1
Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease.
Resumen de: US2025275995A1
The present invention generally relates to the treatment of Parkinson's disease (PD) in humans. More particularly, it relates to nicotinamide riboside (NR) for use in a method for treatment of Parkinson's disease in a human subject characterized by a particular dosage regimen; pharmaceutical compositions; and dosage forms, which can be for use in or as treatment of Parkinson's disease.
Nº publicación: US2025276011A1 04/09/2025
Solicitante:
THE SALLIE ASTOR BURDINE BREAST FOUND [US]
The Sallie Astor Burdine Breast Foundation
Resumen de: US2025276011A1
The present disclosure provides, among other things, methods for the treatment of neurodegenerative diseases (ND) and other mitochondrial disorders, and compositions related thereto. Described herein are in vitro (cell culture) and in vivo (animal model) experimental examples demonstrating mitochondrial organelle transplantation (MOT) for the treatment of NDs such as amyotrophic lateral sclerosis (ALS). Furthermore, as discussed herein, MOT has been performed in five human ALS patients with positive results—measurable improvement of their conditions has been observed, with no adverse events.
BOPI
Sede Electrónica
